Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Timothy G St Pierre, PhD, Amal El-Beshlawy, MD, Mohsen Saleh Elalfy, MD, Abdullah Al Jefri, MD, Kusai Al Zir, MD, Shahina Daar, MD, Dany Habr, MD, Ulrike Kriemler-Krahn, Ali Taher, MD

Blood (2010) 116 (21): 2053.

https://doi.org/10.1182/blood.V116.21.2053.2053

Published: 2010

Journal Articles

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dany Habr, Abdel Hmissi, Amal El-Beshlawy

Blood (2008) 112 (11): 3879.

https://doi.org/10.1182/blood.V112.11.3879.3879

Published: 2008

Journal Articles

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Ali Taher, Amal El-Beshlawy, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Dany Habr, Ulrike Kriemler-Krahn, Abdel Hmissi, Abdullah Al Jefri

Blood (2008) 112 (11): 5409.

https://doi.org/10.1182/blood.V112.11.5409.5409

Published: 2008

Journal Articles

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Ali Taher, Abdullah Al Jefri, Mohsen Saleh Elalfy, Kusai Al Zir, Shahina Daar, Ghazi Damanhouri, Ulrike Kriemler-Krahn, Dietrich Pfluger, Dominik Hadler, Amal El-Beshlawy

Blood (2007) 110 (11): 2779.

https://doi.org/10.1182/blood.V110.11.2779.2779

Published: 2007

Journal Articles

Deferasirox (Exjade ® , ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial.

Ali Taher, Amal El-Beshlawy, Abdullah Al Jefri, Mohsen El Alfy, Kusai Al Zir, Shahina Daar, Ghazi Al-Damanhouri, Dietrich Hadler, Ulrike Krahn

Blood (2005) 106 (11): 3840.

https://doi.org/10.1182/blood.V106.11.3840.3840

Published: 2005

NARROW

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Deferasirox (Exjade ® , ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial.

Email alerts

ASH Publications

American Society of Hematology

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Non-Invasive Measurement of Liver Iron Concentration

Deferasirox (Exjade ® ) Treatment in Pediatric β-Thalassemia Patients with High Iron Burden: 2.8 Years Results from ESCALATOR Trial

Efficacy and Safety of Once-Daily Oral Deferasirox (Exjade ® ) during a Median of 2.7 Years of Treatment in Heavily Iron-Overloaded Patients with β-Thalassemia

Oral Deferasirox (Exjade®, ICL670) Is Effective, with a Clinically Manageable Safety Profile, in Pediatric β-Thalassemia Patients with High Iron Burden.

Deferasirox (Exjade ® , ICL670) Treatment of Inadequately Chelated β-Thalassemia Patients from the Middle East: The ESCALATOR Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only